Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Mirna Therapeutics (MIRN) Share Price

News stories about Mirna Therapeutics (NASDAQ:MIRN) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mirna Therapeutics earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.7925719207299 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Mirna Therapeutics (NASDAQ MIRN) traded down 2.33% on Friday, hitting $1.68. The stock had a trading volume of 14,142 shares. The company has a 50-day moving average price of $1.70 and a 200-day moving average price of $1.89. Mirna Therapeutics has a 52 week low of $1.12 and a 52 week high of $3.36. The stock’s market capitalization is $35.04 million.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Mirna Therapeutics (MIRN) Share Price” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/08/19/mirna-therapeutics-mirn-given-coverage-optimism-score-of-0-10-updated.html.

About Mirna Therapeutics

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

Insider Buying and Selling by Quarter for Mirna Therapeutics (NASDAQ:MIRN)

What are top analysts saying about Mirna Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mirna Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit